Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 6/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.79 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.79 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.79 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.79 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.79 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.79 |
| ▸ | PGR | P06401 | 1/20 | 0.79 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.79 |
| ▸ | RXRA | P19793 | 1/20 | 0.79 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.79 |
| ▸ | CCKAR | P32238 | 1/20 | 0.79 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.79 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.79 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.75 |
| ▸ | LMNA | P02545 | 1/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL557746 | 1.00 | HMGCR (0.79) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| SCHEMBL556017 | 1.00 | HMGCR (0.79) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| SCHEMBL556712 | 1.00 | HMGCR (0.79) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| SCHEMBL4905705 | 1.00 | HMGCR (0.79) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| SCHEMBL4905717 | 1.00 | HMGCR (0.79) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| SCHEMBL557747 | 1.00 | HMGCR (0.79) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| SCHEMBL31517689 | 0.92 | HMGCR (0.66) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| SCHEMBL31517670 | 0.92 | HMGCR (0.66) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| SCHEMBL31517758 | 0.91 | HMGCR (0.65) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| SCHEMBL31517725 | 0.91 | HMGCR (0.65) | HMGCRCYP2C9SIRT6NR4A2PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2419407-B1 | IMPROVED PROCESS FOR THE PREPARATION OF FLUVASTATIN AND SALTS THEREOF | PHARMATHEN SA (GR) | 2012-11-14 | — | — | EP | claimed |
| EP-2419407-A1 | IMPROVED PROCESS FOR THE PREPARATION OF FLUVASTATIN AND SALTS THEREOF | Pharmathen S.A. (GR) | 2012-02-22 | — | — | EP | claimed |
| US-20120035374-A1 | PROCESS FOR THE PREPARATION OF FLUVASTATIN AND SALTS THEREOF | PHARMATHEN S.A. (GR) | 2012-02-09 | — | — | US | claimed |
| WO-2010118757-A1 | IMPROVED PROCESS FOR THE PREPARATION OF FLUVASTATIN AND SALTS THEREOF | PHARMATHEN S.A. (GR) | 2010-10-21 | — | — | WO | claimed |
| US-8835486-B2 | Pharmaceutical formulation containing an HMG-COA reductase inhibitor and method for the preparation thereof | PHARMATHEN S.A. (GR) | 2014-09-16 | — | — | US | disclosed |
| CN-101250153-B | Technique for preparing fluvastatin sodium crystal system | SHENZHEN SALUBRIS PHARM CO LTD | 2013-09-18 | — | — | CN | disclosed |
| EP-1928425-B1 | Pharmaceutical formulation containing fluvastatin | PHARMATHEN SA (GR) | 2013-01-23 | — | — | EP | disclosed |
| EP-2419407-B1 | IMPROVED PROCESS FOR THE PREPARATION OF FLUVASTATIN AND SALTS THEREOF | PHARMATHEN SA (GR) | 2012-11-14 | — | — | EP | disclosed |
| EP-2419407-A1 | IMPROVED PROCESS FOR THE PREPARATION OF FLUVASTATIN AND SALTS THEREOF | Pharmathen S.A. (GR) | 2012-02-22 | — | — | EP | disclosed |
| US-20120035374-A1 | PROCESS FOR THE PREPARATION OF FLUVASTATIN AND SALTS THEREOF | PHARMATHEN S.A. (GR) | 2012-02-09 | — | — | US | disclosed |
| WO-2010118757-A1 | IMPROVED PROCESS FOR THE PREPARATION OF FLUVASTATIN AND SALTS THEREOF | PHARMATHEN S.A. (GR) | 2010-10-21 | — | — | WO | disclosed |
| US-20100137400-A1 | PHARMACEUTICAL FORMULATION CONTAINING AN HMG-COA REDUCTASE INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | PHARMATHEN S.A. (GR) | 2010-06-03 | — | — | US | disclosed |
| WO-2006109147-A1 | SUBSTANTIALLY PURE AMORPHOUS FLUVASTATIN, PROCESSES FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | GLENMARK PHARMACEUTICALS LIMITED (US) | 2006-10-19 | — | — | WO | disclosed |
| EP-1667968-A1 | PROCESSES FOR THE PREPARATION OFA POLYMORPH OF FLUVASTATIN SODIUM | Teva Pharmaceutical Industries Limited (IL) | 2006-06-14 | — | — | EP | disclosed |
| EP-1638937-A2 | FLUVASTATIN SODIUM CRYSTAL FORMS XIV, LXXIII,LXXIX, LXXX AND LXXXVII, PROCESSES FOR PREPARING THEM, COMPOSITIONS CONTAINING THEM AND METHODS OF USING THEM | Teva Pharmaceutical Industries Limited (IL) | 2006-03-29 | — | — | EP | disclosed |
| WO-2006030304-A2 | NOVEL FORMS OF FLUVASTATIN SODIUM, PROCESSES FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF | RANBAXY LABORATORIES LIMITED (IN) | 2006-03-23 | — | — | WO | disclosed |
| US-20050119342-A1 | Process for the preparation of fluvastatin sodium crystal form XIV | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-06-02 | — | — | US | disclosed |
| WO-2005040113-A1 | PROCESSES FOR THE PREPARATION OF A POLYMORPH OF FLUVASTATIN SODIUM | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-05-06 | — | — | WO | disclosed |
| US-20050038114-A1 | Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-02-17 | — | — | US | disclosed |
| WO-2004113291-A2 | FLUVASTATIN SODIUM CRYSTAL FORMS XIV, LXXIII,LXXIX, LXXX AND LXXXVII, PROCESSES FOR PREPARING THEM, COMPOSITIONS CONTAINING THEM AND METHODS OF USING THEM | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038114-A1 | Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them | LPXN, PCSK9, CYP4A11 | HMGCR 8/4885CYP2C9 27/4885SIRT6 1568/4885 |
| US-20120035374-A1 | PROCESS FOR THE PREPARATION OF FLUVASTATIN AND SALTS THEREOF | HMGCR, CETP, PCSK9 | HMGCR 1/4885CYP2C9 61/4885SIRT6 1760/4885 |
| US-20050119342-A1 | Process for the preparation of fluvastatin sodium crystal form XIV | CYP4F11, CYP4A11, CYP4F3 | HMGCR 5/4885CYP2C9 23/4885SIRT6 2721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.